Grifols SA (GRFS) AI Stock Analysis

• Market Cap: $8.51B
• Dividend Yield: 1.48%
• Average Volume (3M): 522.34K
• Price to Earnings (P/E): 20.3
• Beta (1Y): 0.97
• Revenue Growth: 10.05%
• EPS Growth: 98.22%
• Country: US
• Employees: 23,833
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.20
• Shares Outstanding: 261,425,100
• 10 Day Avg. Volume: 484,531
• 30 Day Avg. Volume: 522,337
• PEG Ratio: 0.19
• Price to Book (P/B): 0.83
• Price to Sales (P/S): 0.68
• P/FCF Ratio: 9.20
• Enterprise Value/Market Cap: 2.21
• Enterprise Value/Revenue: 2.53
• Enterprise Value/Gross Profit: 6.40
• Enterprise Value/Ebitda: 12.44
• 1Y Price Target: $10.00
• Price Target Upside: 3.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: $10.00 ▲(3.63% Upside)

Grifols SA's overall stock score is driven by strong earnings call results and improving financial performance, despite high leverage and moderate valuation. Technical indicators suggest a neutral market position, while the reinstatement of dividends signals confidence in future growth.

Grifols SA Business Overview & Revenue Model

Company Description

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

How the Company Makes Money

Grifols generates revenue primarily through the sale of its plasma-derived products, which are a significant portion of its revenue. The company operates a robust network of human plasma collection centers, which allows it to secure a steady supply of plasma for its manufacturing processes. Key revenue streams include sales from its Bioscience division, which provides therapies for patients with immune deficiencies and other chronic conditions. Additionally, Grifols earns revenue from its Diagnostic and Hospital segments, which offer a range of products and services for hospitals and laboratories. The company has established significant partnerships with healthcare institutions and organizations, enhancing its market reach and facilitating the distribution of its products. Factors contributing to Grifols' earnings include the increasing demand for blood products globally, advancements in biotechnology, and the company's commitment to research and development, which drives innovation and the introduction of new therapies.

Grifols SA Financial Statement Overview

Summary

Grifols SA exhibits robust revenue growth and improved operating margins, yet struggles with a low net profit margin. The balance sheet shows high leverage, which requires careful management to mitigate financial risks. Strong cash flow generation is a positive, although further enhancement could bolster financial stability. Overall, the financial health of Grifols SA is improving but needs ongoing attention to margins and leverage.

Income Statement

Grifols SA demonstrates strong revenue growth with a 9.41% increase from 2023 to 2024. The gross profit margin improved to 38.74%, indicating efficient cost management. However, the net profit margin remains relatively low at 2.18%, suggesting potential cost or operational inefficiencies. The EBIT margin increased to 16.53%, reflecting better operating performance.

Balance Sheet

The debt-to-equity ratio of 1.71 indicates a high level of leverage, which could pose risks if not managed properly. Return on equity is modest at 2.67%, suggesting room for improvement in profitability. The equity ratio of 27.49% highlights a stable asset base supported by equity, though there is reliance on debt.

Cash Flow

Grifols SA shows a significant improvement in free cash flow, turning positive in 2024. The operating cash flow to net income ratio of 5.75 reflects strong cash generation capacity relative to net profits. However, the free cash flow to net income ratio of 3.38 indicates that cash flow improvements are still needed to enhance financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.45B	7.21B	6.59B	6.06B	4.93B	5.34B
Gross Profit	2.94B	2.79B	2.32B	2.21B	1.96B	2.26B
EBITDA	1.51B	1.48B	1.18B	1.08B	922.47M	1.30B
Net Income	297.45M	156.92M	59.31M	208.28M	188.73M	618.55M
Balance Sheet
Total Assets	19.77B	21.41B	21.44B	21.53B	19.23B	15.27B
Cash, Cash Equivalents and Short-Term Investments	565.80M	1.00B	646.04M	580.24M	2.68B	590.51M
Total Debt	8.82B	10.09B	10.97B	9.75B	9.32B	6.91B
Total Liabilities	12.17B	12.80B	13.47B	13.08B	11.09B	8.55B
Stockholders Equity	5.17B	5.88B	5.83B	5.65B	5.52B	5.11B
Cash Flow
Free Cash Flow	768.57M	530.80M	-87.14M	-386.43M	281.89M	747.78M
Operating Cash Flow	1.10B	902.17M	218.69M	-10.87M	596.98M	1.11B
Investing Cash Flow	-679.71M	886.67M	-394.72M	-1.98B	-29.39M	-858.12M
Financing Cash Flow	-1.90B	-1.36B	171.49M	-173.49M	2.30B	-354.40M

Grifols SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.65
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Positive. The current price of 9.65 is below the 20-day moving average (MA) of 9.72, below the 50-day MA of 9.93, and above the 200-day MA of 8.47, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.06 is Neutral, neither overbought nor oversold. The STOCH value of 62.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRFS.

Grifols SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GILD	78 Outperform	$146.23B	23.44	33.26%	2.56%	3.69%	501.26%
GSK	78 Outperform	$88.22B	20.15	23.04%	3.75%	3.46%	-13.29%
SNY	76 Outperform	$122.73B	12.44	8.39%	4.37%	-9.32%	120.62%
AMGN	70 Outperform	$159.25B	24.20	99.14%	3.14%	13.10%	110.67%
GRFS	67 Neutral	$8.51B	20.33	5.41%	1.48%	10.05%	98.22%
BMY	66 Neutral	$88.32B	17.51	29.31%	5.68%	2.57%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Grifols SA Corporate Events

Grifols Reports Strong H1 2025 Results with Revenue and Profit Growth

On July 29, 2025, Grifols announced its half-year financial results for 2025, showcasing a 7% increase in revenues to EUR 3,677 million and a nearly fourfold rise in net profit to EUR 177 million, driven by strong performance in its Biopharma segment. The company also reduced its leverage ratio and reinstated a dividend payment, reflecting its commitment to shareholder returns. Grifols plans to launch Fibrinogen in Europe and the U.S. following FDA approval, and it has completed the delisting of Biotest from the Frankfurt Stock Exchange, increasing its equity stake to 80.32%. The company remains focused on its Value Creation Plan, leveraging its business model to mitigate potential impacts from trade tariffs.

Grifols Announces Interim Dividend for 2025

On July 28, 2025, Grifols, S.A.’s Board of Directors approved an interim dividend payment of €0.15 per share for the 2025 profit. The payment will be distributed on August 13, 2025, with a total dividend amounting to €102,076,365.60. This decision reflects Grifols’ commitment to providing value to its shareholders and may impact investor sentiment positively.

Grifols Expands Committee Focus to Include Corporate Reputation

On July 28, 2025, Grifols, S.A.’s Board of Directors resolved to amend its internal regulations, renaming the Sustainability Committee to the ‘Sustainability, Communication and Reputation Committee.’ This change expands the committee’s authority to include the supervision of the company’s corporate reputation. The updated regulations will be communicated to the National Securities Market Commission and filed with the Commercial Registry of Barcelona, with further details to be shared at the next General Shareholders’ Meeting.